Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225577 | 0.85 | SIGMAR1 (0.40) | SIGMAR1MAPTGRM6GBA1OPRM1 | |
| SCHEMBL8142711 | 0.82 | GBA1 (0.46) | SIGMAR1MAPTGRM6GBA1SPHK2 | |
| SCHEMBL12187945 | 0.79 | SIGMAR1 (0.42) | SIGMAR1MAPTGRM6GBA1DRD2 | |
| SCHEMBL14885473 | 0.79 | GRM6 (0.43) | SIGMAR1MAPTGRM6GBA1OPRK1 | |
| SCHEMBL8224955 | 0.79 | GRM6 (0.43) | SIGMAR1MAPTGRM6GBA1OPRK1 | |
| SCHEMBL2805318 | 0.78 | SIGMAR1 (0.41) | SIGMAR1MAPTGRM6GBA1SPHK2 | |
| SCHEMBL4563595 | 0.78 | SIGMAR1 (0.41) | SIGMAR1MAPTGRM6GBA1SPHK2 | |
| SCHEMBL12163773 | 0.78 | SIGMAR1 (0.41) | SIGMAR1MAPTGRM6GBA1SPHK2 | |
| SCHEMBL16716374 | 0.78 | SIGMAR1 (0.41) | SIGMAR1MAPTGRM6GBA1SPHK2 | |
| SCHEMBL8159118 | 0.77 | SIGMAR1 (0.41) | SIGMAR1MAPTGRM6GBA1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | SIGMAR1 258/4885MAPT 1378/4885GRM6 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.